Novo Nordisk v. Rio Biopharmaceuticals & EMS: Ozempic® Semaglutide Patent Suit Dismissed
Novo Nordisk A/S brought a 10-patent infringement action in Delaware against Rio Biopharmaceuticals and EMS, SA, asserting exclusivity over its blockbuster Ozempic® semaglutide injection. After 1,015 days of litigation, all claims were dismissed without prejudice under a court-ordered settlement, leaving the patents intact and future enforcement options open.
A 10-Patent Semaglutide Battle Ends in Negotiated Dismissal
On March 4, 2022, Novo Nordisk A/S filed suit in the Delaware District Court against Rio Biopharmaceuticals, Inc. and Brazilian pharmaceutical company EMS, SA, asserting infringement of ten U.S. patents covering semaglutide injection formulations and related drug delivery device technology — the IP backbone of its Ozempic® product line. The asserted patents span application dates ranging across multiple generations of semaglutide development, reflecting Novo Nordisk’s layered IP strategy in the GLP-1 receptor agonist space.
On December 13, 2024, the court entered a Stipulation and Order of Dismissal resolving the action. All claims, counterclaims, affirmative defenses, and demands were dismissed without prejudice and without costs or attorneys’ fees to any party. The parties waived any right to appeal the dismissal. The court retained jurisdiction to enforce the underlying settlement agreement, confirming that a private settlement — whose terms remain confidential — drove the resolution.
The 1,015-day duration suggests substantive litigation activity before the parties reached accommodation, consistent with the complexity of a 10-patent portfolio action involving a global blockbuster drug. A without-prejudice dismissal preserves Novo Nordisk’s ability to re-file if any agreed conditions are breached, a standard enforcement backstop in pharma settlement structures. The precise commercial terms — including any licensing, market-entry, or consent-to-launch provisions — are not disclosed in the public record.
Filing to Dismissed without Prejudice in 1015 days
1,015 days — nearly 2.8 years from filing to dismissal, above median for multi-patent pharma cases in Delaware
Dismissed without prejudice: what the settlement order means for both parties
Without-prejudice dismissal preserves Novo Nordisk’s enforcement rights
A dismissal without prejudice means no final judgment was entered on the merits. Novo Nordisk retains the right to re-file infringement claims on the same patents if the settlement conditions — which remain confidential — are not honoured. This is a standard risk-management tool in branded pharmaceutical settlements where agreed launch windows or licensing terms must be monitored over time.
No merits adjudicationWithout prejudice vs. with prejudice: what the public record reveals
The order explicitly states ‘without prejudice,’ meaning the dismissal does not bar future litigation on the same patents and claims. Had it been with prejudice, Novo Nordisk would have been permanently barred from reasserting these ten patents against these defendants on the same products. The without-prejudice structure, combined with court-retained jurisdiction to enforce the settlement, strongly suggests a structured licensing or consent-to-launch agreement governs the relationship going forward.
Re-filing right preservedRio Biopharmaceuticals and EMS avoid a damages judgment — but on negotiated terms
The defendants secured dismissal without any public finding of infringement and without costs awarded against them. However, without-prejudice dismissal typically signals that the resolution is conditional. Any commercial access to the semaglutide market — if granted — is likely subject to undisclosed restrictions. The patent validity of all ten Novo Nordisk patents remains legally unchallenged by this outcome.
No invalidity findingNovo Nordisk’s semaglutide IP wall remains intact for GLP-1 market entrants
With no patents invalidated or limited by this proceeding, the ten-patent portfolio covering Ozempic® semaglutide injection and delivery device technology emerges structurally undiminished. Prospective generic and biosimilar filers in the GLP-1 agonist space face the same assertion risk from this portfolio. The settlement outcome suggests Novo Nordisk is willing to negotiate access under undisclosed terms rather than litigate to final judgment — a posture relevant to future ANDA or 505(b)(2) applicants targeting semaglutide.
Portfolio enforcement risk persistsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novo Nordisk A/S | Individual | Global pharmaceutical innovator — holder of 10 semaglutide injection and delivery device patentsSearch in Eureka ↗ |
| Co-Plaintiff | Novo Nordisk A/S | Individual | Search in Eureka ↗ |
| Defendant | Rio Biopharmaceuticals, Inc. | Company | Rio Biopharmaceuticals, Inc. (U.S.) and EMS, SA (Brazil) — generic/biosimilar semaglutide developersSearch in Eureka ↗ |
| Co-Defendant | EMS, SA | Company | Search in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff counsel | Travis J. Murray | Attorney | Counsel for Novo Nordisk A/SSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Novo Nordisk A/SSearch in Eureka ↗ |
| Defendant counsel | Aaron M. Johnson | Attorney | Counsel for Rio Biopharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Jaimin H. Shah | Attorney | Counsel for Rio Biopharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Kenneth Laurence Dorsney | Attorney | Counsel for Rio Biopharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Philip Y. Kouyoumdjian | Attorney | Counsel for Rio Biopharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Stephen R. Auten | Attorney | Counsel for Rio Biopharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Morris James LLP | Law Firm | Representing Rio Biopharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The December 13, 2024 Stipulation and Order of Dismissal reflects a negotiated resolution rather than a merits adjudication. The court’s explicit retention of jurisdiction to enforce the settlement agreement is legally significant: it converts what would otherwise be a purely private contract into a court-enforceable obligation, giving Novo Nordisk a swift enforcement mechanism if defendants breach settlement terms. The express waiver of appeal rights by both parties forecloses any future procedural challenge to the dismissal itself. No finding was made on infringement, validity, or enforceability of any of the ten asserted patents.
US8129343B2 — Semaglutide GLP-1 formulation and prefilled delivery device patents
The ten asserted patents collectively cover Novo Nordisk’s semaglutide technology platform, spanning GLP-1 receptor agonist peptide chemistry, injectable solution formulation at clinical concentrations (1.34 mg/ml), and the prefilled pen delivery devices used in Ozempic® administration. The portfolio includes a reissue patent (USRE046363E), indicating Novo Nordisk has actively broadened or corrected claim scope post-grant — a tactic that signals defensive IP management. Application dates across the portfolio suggest continuous innovation from early compound development through commercialised delivery systems.
For competitors and generic developers, this patent wall represents one of the most commercially significant GLP-1 IP portfolios currently in force. Ozempic® generated billions in annual revenue, making the semaglutide formulation and device patents high-value enforcement assets. The portfolio’s multi-layer structure — covering both the active pharmaceutical ingredient technology and the delivery mechanism — means design-around strategies are materially constrained. Any ANDA or biosimilar pathway targeting semaglutide at U.S. clinical concentrations must navigate this cluster of overlapping claims.
Should you run an FTO against the Novo Nordisk semaglutide patent portfolio?
Any pharmaceutical company, contract manufacturer, or device developer involved in GLP-1 receptor agonist products — particularly semaglutide-based injectables or prefilled pen delivery systems — should treat this portfolio as an active clearance priority. The ten patents span formulation chemistry, dosing concentrations, and device mechanics, meaning both API manufacturers and device suppliers face independent exposure. This case confirms Novo Nordisk will pursue both U.S. and international entities that file for U.S. market entry.
PatSnap Eureka’s FTO Search Agent can map each of the ten asserted patents against your product specifications, flag claim overlap at the formulation and device levels, and identify prior art that has been or could be deployed against these patents. Eureka’s claim charting and portfolio landscape tools let R&D and IP teams run structured clearance analysis on the full semaglutide patent cluster — before committing to an ANDA, 505(b)(2), or biosimilar regulatory strategy.
Run a freedom-to-operate analysis on US8129343B2 to assess your product’s exposure
Run FTO in Eureka →Similar GLP-1 and semaglutide patent infringement cases in U.S. federal courts
Cases involving GLP-1 receptor agonist formulation patents and prefilled injection device IP litigated in Delaware District Court and comparable first-instance pharmaceutical forums.
What this case signals for the GLP-1 and semaglutide IP landscape
Ten asserted patents, a global blockbuster drug, and a confidential settlement — here is what IP teams tracking semaglutide should take away.
Novo Nordisk’s layered semaglutide portfolio is actively enforced
With ten patents spanning formulation and device technology, Novo Nordisk has demonstrated a willingness to assert the full breadth of its Ozempic® IP against both U.S.-based and international generic entrants. Companies developing semaglutide generics or biosimilars should map each asserted patent before committing to regulatory filings.
Without-prejudice settlement creates ongoing compliance obligations for defendants
The court’s retained jurisdiction over the settlement agreement means Rio Biopharmaceuticals and EMS operate under court-enforceable conditions. For IP counsel advising clients in the GLP-1 space, this structure signals that negotiated entry — not litigation victory — is the most likely path to market, at least in the near term.
A/S v Rio — key questions answered
The case was dismissed without prejudice on December 13, 2024, pursuant to a Stipulation and Order of Dismissal. No costs, disbursements, or attorneys’ fees were awarded to any party. The court retained jurisdiction to enforce the underlying private settlement agreement. No finding was made on infringement or validity of any of the ten asserted semaglutide patents.
Novo Nordisk asserted ten U.S. patents: US8129343B2, US10335462B2, US11097063B2, USRE046363E, US9775953B2, US9457154B2, US10220155B2, US9132239B2, US9687611B2, and US8920383B2. These patents collectively cover semaglutide GLP-1 formulation chemistry, injectable solution concentrations, and prefilled pen drug delivery device technology underlying Ozempic®.
A without-prejudice dismissal means no final judgment on the merits was entered, and Novo Nordisk retains the right to re-file infringement claims on the same ten patents against these defendants if settlement conditions are breached. This contrasts with a with-prejudice dismissal, which would permanently bar re-litigation of the same claims. The court’s retained jurisdiction over the settlement further reinforces Novo Nordisk’s enforcement position.
EMS, SA is a Brazilian pharmaceutical company. Its inclusion as a defendant alongside U.S.-based Rio Biopharmaceuticals suggests that the defendants were jointly developing or seeking to commercialise a semaglutide injection product targeting the U.S. market. Novo Nordisk’s willingness to name an international entity in U.S. district court proceedings is consistent with its broader cross-border enforcement posture for its GLP-1 portfolio.
No. A without-prejudice dismissal by stipulation does not constitute any finding on the validity, enforceability, or infringement of any of the ten asserted patents. All ten semaglutide patents remain in force and legally unchallenged by this proceeding. Novo Nordisk retains full enforcement rights against third parties, and the patents continue to pose assertion risk to any company seeking to enter the U.S. semaglutide market.
PatSnap Eureka searches patents and litigation data to answer instantly.